Medigene AG (0QGJ.L)
- GlobeNewswire
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents the company’s proprietary T cell receptor (TCR) discovery process to obtain optimal affinity 3S (sensitive, specific and safe) TCRs at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting in Mainz from May 15 - 17, 2024. Data presented also show
- GlobeNewswire
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024Use of proceeds from recent capital raise further advances plans for first patient enrollment in MDG1015 Phase 1 dose escalation trial by end of 2024, subject to additional financing Planegg/Martinsried, May 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-onco
- GlobeNewswire
Medigene to Present at Upcoming Conferences
Planegg/Martinsried, May 7, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024. 21st CIMT Annual Meeting htt
